Philip Drake May 18, 2017 Brilacidin Cellceutix Completes Patient Enrollment of Final Cohort in Phase 2 Trial of Brilacidin for Inflammatory Bowel Disease; Topline Results Anticipated in July
Philip Drake April 10, 2017 Brilacidin Cellceutix CEO Discusses Brilacidin Following Interim Trial Results for Treating Oral Mucositis and Inflammatory Bowel Disease
Syed Muhammad ObaidUllah March 27, 2017 Brilacidin Cellceutix Reports Very Encouraging Interim Analysis of Phase 2 Drug Candidate Brilacidin for Severe Oral Mucositis (OM) in Head and Neck Cancer Patients; High Potential for Preventative Treatment
Philip Drake March 21, 2017 Brilacidin Cellceutix Releases Favorable Topline Findings as Part of Interim Analysis of Phase 2 Drug Candidate Brilacidin for the Treatment of Inflammatory Bowel Disease
Philip Drake March 16, 2017 Brilacidin Cellceutix’s Phase 2 Drug Candidate Brilacidin Emerging as a Potential Novel Non-Biologic Therapy in Treating Inflammatory Bowel Disease
Philip Drake March 8, 2017 Brilacidin Cellceutix Releases Preliminary Efficacy and Safety Data in Interim Analysis of First Two Cohorts in Phase 2 Trial of Brilacidin for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis
Philip Drake February 22, 2017 Brilacidin Cellceutix Phase 2 Brilacidin Trial Progresses to Highest Dose Cohort for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis
Philip Drake January 23, 2017 Brilacidin Cellceutix’s Brilacidin Demonstrates Promise in Treating Ulcerative Colitis Supported by Endoscopic Assessment, Patient-Reported Outcomes
Philip Drake January 17, 2017 Brilacidin Cellceutix Completes Enrollment in Second of Three Planned Cohorts in Phase 2 Clinical Trial of Brilacidin for Inflammatory Bowel Disease
Philip Drake January 4, 2017 Corporate, Brilacidin Cellceutix to Present at Biotech Showcase 2017; Brilacidin for Oral Mucositis Nears Interim Results
Philip Drake December 7, 2016 Brilacidin Cellceutix Phase 2 Trial Dose Escalates in 2nd Cohort for Brilacidin as a Novel Anti-Inflammatory Drug Candidate for Ulcerative Colitis
Daniel Pizza October 26, 2016 Prurisol, Brilacidin Cellceutix Novel Anti-Inflammatory Phase 2 Drug Candidate Brilacidin Builds Momentum Across Multiple Clinical Indications
Daniel Pizza October 10, 2016 Brilacidin Cellceutix Phase 2 Trial Initial Data Shows Potential of Brilacidin as a Novel Anti-Inflammatory Drug Candidate for Induction of Remission of Mild-to-Moderate Ulcerative Colitis
Daniel Pizza July 21, 2016 Brilacidin Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis
Daniel Pizza July 18, 2016 Brilacidin Cellceutix Receives Update on First Patient Enrollment in Phase 2 Proof-of-Concept Study of Brilacidin for Ulcerative Proctitis
Daniel Pizza June 15, 2016 Brilacidin Cellceutix Starts Phase 2 Trial of Brilacidin as a Novel Therapy for Ulcerative Proctitis
Daniel Pizza March 30, 2016 Brilacidin Cellceutix Receives Preliminary Approval for Clinical Trial of Brilacidin for Ulcerative Proctitis
Daniel Pizza February 26, 2016 Brilacidin Cellceutix Submits Special Protocol Assessment Request to FDA for Phase 3 Clinical Trial of Brilacidin for ABSSSI
Philip Drake January 14, 2016 Brilacidin Brilacidin Lyophilized as Cellceutix Prepares to Bring First New Class of Antibiotic to Phase 3 Trials in More than 20 Years
Philip Drake December 11, 2015 Brilacidin Cellceutix Completes Lab Testing of Brilacidin for Planned Phase 3 Trial for Acute Bacterial Skin and Skin Structure Infections
